seperator

PD DR. CARSTEN RUDOLPH

seperator

Chief Executive Officer ad interim

Dr. Carsten Rudolph, PhD is a co-founder of Ethris and the lead inventor of its SNIM® RNA Technology. His deep expertise is delivering mRNA specifically to the lungs. He is the inventor of 15 patents/applications and has authored more than 120 scientific publications. Carsten is affiliated with the Dr. von Haunerschen Kinderhospital of the Ludwig Maximilians University (LMU) in Munich. He obtained his pharmaceutical degree from Freie Universität (FU) Berlin.

seperator

PD DR. CARSTEN RUDOLPH

seperator

Chief Executive Officer ad interim

Dr. Carsten Rudolph, PhD is a co-founder of Ethris and the lead inventor of its SNIM® RNA Technology. His deep expertise is delivering mRNA specifically to the lungs. He is the inventor of 15 patents/applications and has authored more than 120 scientific publications. Carsten is affiliated with the Dr. von Haunerschen Kinderhospital of the Ludwig Maximilians University (LMU) in Munich. He obtained his pharmaceutical degree from Freie Universität (FU) Berlin.

seperator

PROF. DR. CHRISTIAN PLANK

seperator

Chief Technology Officer

Prof. Dr. Christian Plank, PhD is a co-founder of Ethris and brings a broad expertise in targeted drug delivery. He is the author of more than 170 publications and co-inventor of numerous patents in the field of nucleic acid delivery. Christian is a Professor at the Technical University of Munich and obtained his PhD in biochemistry from the University of Vienna, Austria.

seperator

DR. MED. THOMAS LANGENICKEL

seperator

Chief Medical Officer

Dr. med. Thomas Langenickel, MD, has more than 15 years of experience in clinical development and translational medicine in cardiovascular and respiratory disease areas. He previously held the position of Executive Director and Head of Respiratory Profiling at Novartis AG and served as Medical Director at Bristol-Myers Squibb. He obtained his MD and PhD at the Humboldt University of Berlin, trained in Clinical Pharmacology and Internal Medicine/Cardiology at the Max-Delbrück Center for Molecular Medicine and the Charité Hospital in Berlin, Germany. He previously completed a post-doctoral fellowship at the National Heart, Lung and Blood Institute in Bethesda, USA.

seperator

DR. MED. THOMAS LANGENICKEL

seperator

Chief Medical Officer

Dr. med. Thomas Langenickel, MD, has more than 15 years of experience in clinical development and translational medicine in cardiovascular and respiratory disease areas. He previously held the position of Executive Director and Head of Respiratory Profiling at Novartis AG and served as Medical Director at Bristol-Myers Squibb. He obtained his MD and PhD at the Humboldt University of Berlin, trained in Clinical Pharmacology and Internal Medicine/Cardiology at the Max-Delbrück Center for Molecular Medicine and the Charité Hospital in Berlin, Germany. He previously completed a post-doctoral fellowship at the National Heart, Lung and Blood Institute in Bethesda, USA.

Join the Team.

CONTACT